NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

NanoString Technologies Inc

SEATTLE--(BUSINESS WIRE)-- #AACR24--NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024. NanoString and its customers will showcase 110 posters and highlight its products.

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (OTC: NSTGQ) (“NanoString”), a leading provider of life science tools for discovery and translational research, today announced that the European Unified Patent Court (“UPC”) Court of Appeal overturned a preliminary injunction that was previously issued by the Munich local division of the UPC in September and was impacting NanoString's CosMx™ Spatial Molecular Imager (SMI) products in the EU. The decision allows NanoString to immediately r.

European UPC Court of Appeal Overturns Injunction Impacting NanoString's CosMx Products, Company to Immediately Resume Sales in 16 EU Countries

Life science applications specialist NanoString (NASDAQ: NSTG ), which provides tools for discovery and translation research, announced that it has entered into a credit agreement with its existing lenders. Driving the need for such an arrangement was a bankruptcy filing at the beginning of the week.

Why Is NanoString (NSTG) Stock Up 115% Today?

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loa.

NanoString Announces Completion of Financing to Support Restructuring Process

Investors looking at today's price action in NanoString (NASDAQ: NSTG ) stock ought to be shaking their heads in amazement. Indeed, after announcing the company would be filing for bankruptcy protection on Monday, many thought the story with NanoString was over.

Why Is NanoString (NSTG) Stock Up 180% Today?

Seattle-based publicly traded biotech company NanoString Technologies announced Monday that it has initiated a Chapter 11 bankruptcy plan and is exploring a potential sale in the latest fallout from its loss in a patent infringement case against 10X Genomics.

NanoString stock sinks 70% as Seattle biotech company enters bankruptcy process

NanoString Technologies (NASDAQ: NSTG ) stock is taking a beating on Monday after the company announced a voluntary Chapter 11 bankruptcy filing. NanoString Technologies notes that this bankruptcy filing is the result of its lost litigation battles against 10x Genomics.

Why Is NanoString Technologies (NSTG) Stock Down 59% Today?

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG) (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to “Map the Universe of Biology.” With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy.

NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology

SEATTLE--(BUSINESS WIRE)-- #AGBT2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), Nan.

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI). The data will be highlighted at the 42nd annual J.P. Morgan Healthcare Conference 2024 in San Francisco during NanoString's corporate presentation on Wednesday, January 10, 20.

NanoString's CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution

Seattle-based publicly traded biotech company NanoString Technologies said in a filing Friday that it plans to cut about 50 positions, or 9% of its workforce.

NanoString Technologies to cut 9% of workforce, gets delisting notice from Nasdaq

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString's Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as mat.

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor.

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference

AudioEye Inc

FlexShopper

Intellicheck

Jerash holdings (US) Inc

One Stop Systems

PASSAGE BIO

Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts.

7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight

10X Genomics

Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.

NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics

SEATTLE--(BUSINESS WIRE)--NanoString Comments on Delaware District Court Verdict.

NanoString Comments on Delaware District Court Verdict

Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG).

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

SEATTLE--(BUSINESS WIRE)--NanoString will present at the Society for Neuroscience meeting new brain research powered by its spatial profiling and spatial imaging platforms.

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

SEATTLE--(BUSINESS WIRE)--NanoString to present at November conferences.

NanoString to Webcast Presentations from Upcoming Healthcare Conferences

NanoString Technologies, Inc. (NASDAQ:NSTG ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Doug Farrell - IR Brad Gray - President and CEO Tom Bailey - CFO Conference Call Participants Marta Nazarovets - JPMorgan Kyle Boucher - TD Cowen Catherine Schulte - Baird Evan Stampler - Stifel Alexander Vukasin - Canaccord Genuity Operator Good afternoon. My name is Krista and I'll be your conference operator today.

NanoString Technologies, Inc. (NSTG) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for NanoString (NSTG) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NanoString (NSTG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports Q3 2023 Operating Results.

NanoString Technologies Releases Operating Results for Third Quarter of 2023

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today the line-up of researchers joining NanoString at the 38th annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held in San Diego, CA. Dr. Aubrey Thompson of the Mayo Clinic and Amaya Pankaj, a research fellow from Dr. David Ting's Lab at Massachusetts General Hospital, will share the first data from NanoString's newest assay for.

NanoString Customers Present First Data Using the Most Comprehensive Spatial Proteomics Panel Available

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2Seventy Bio

In stock trading, shorting is seen as a high-risk, high-reward strategy. This approach involves borrowing stocks, selling them, and betting on their price dropping to make a profit.

News for NanoString Technologies Stock (NSTG)